TRANSCEND CAPITAL ADVISORS, LLC
Position in IKT — Inhibikase Therapeutics, Inc.
CIK 1776082
MADISON, NJ
Position in IKT
as of Jun 30, 2026
· filed Aug 4, 2026
Position Value
$91,954
+$64,895 QoQ
Shares Held
45,298
+181.2% QoQ
Ownership
0.032%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#60
of 106 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in IKT Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026TRANSCEND CAPITAL ADVISORS, LLC holds $6,758,569 across 9 Biotechnology names. IKT ranks #9 (1.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | KRYS |
Krystal Biotech, Inc.
|
6,522 | $2,424,031 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,971 | $1,475,784 | |
| 3 | INCY |
Incyte Corp
|
8,231 | $933,066 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
901 | $561,809 | |
| 5 | TGTX |
Tg Therapeutics, Inc.
|
8,658 | $475,670 | |
| 6 | EXEL |
Exelixis, Inc.
|
6,283 | $341,858 | |
| 7 | CLDX |
Celldex Therapeutics, Inc.
|
6,196 | $230,553 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
3,912 | $223,844 |
All Filings in IKT
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $91,954 | 45,298 | Shares | Sole | 2026-08-04 | |
| 2026-03-31 | $27,059 | 16,107 | Shares | Sole | 2026-05-13 | |
| No filing history on record for this holder in this stock. | ||||||